The outcome of the trial may determine if Alnylam retains exclusive ownership of the trigger IP (Tuschl I and/or Tuschl II patent families) for therapeutic siRNA-mediated gene silencing. There are potentially billions of dollars in partnerships and licensing fees at stake, as well as revenues and royalty fees following successful drug development.
Analysts at Nerac, Inc. will be covering the trial in Boston, which is tentatively scheduled to start in late June. The rulings and hearings leading up to the trial are likely to have a noticeable impact for those working in the Biotechnology and Pharmaceutical industries, technology licensing and transfer offices, investors and scientists interested in the field of RNA interference.
Nerac Analysts will post updates as events occur and daily observations from the trial at http://blog.nerac.com/rnailitigation/
Summaries have already posted on hearings that occurred on April 12th and May 17th as well as important documents and commentary.